Evidence map›Paper›PMID 39834417›Full record

ArticleHeliyon2025

Towards personalized cardiometabolic risk prediction: A fusion of exposome and AI.

Zeinab Shahbazi, Slawomir Nowaczyk

Abstract read
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zeinab ShahbaziCenter for Applied Intelligent Systems Research, Halmstad University, Sweden.
Slawomir NowaczykCenter for Applied Intelligent Systems Research, Halmstad University, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influence of the exposome on major health conditions like cardiovascular disease (CVD) is widely recognized. However, integrating diverse exposome factors into predictive models for personalized health assessments remains a challenge due to the complexity and variability of environmental exposures and lifestyle factors. A machine learning (ML) model designed for predicting CVD risk is introduced in this study, relying on easily accessible exposome factors. This approach is particularly novel as it prioritizes non-clinical, modifiable exposures, making it applicable for broad public health screening and personalized risk assessments. Assessments were conducted using both internal and external validation groups from a multi-center cohort, comprising 3,237 individuals diagnosed with CVD in South Korea within twelve years of their baseline visit, along with an equal number of participants without these conditions as a control group. Examination of 109 exposome variables from participants' baseline visits spanned physical measures, environmental factors, lifestyle choices, mental health events, and early-life factors. For risk prediction, the Random Forest classifier was employed, with performance compared to an integrative ML model using clinical and physical variables. Furthermore, data preprocessing involved normalization and handling of missing values to enhance model accuracy. The model's decision-making process were using an advanced explainability method. Results indicated comparable performance between the exposome-based ML model and the integrative model, achieving AUC of 0.82(+/-)0.01, 0.70(+/-)0.01, and 0.73(+/-)0.01. The study underscores the potential of leveraging exposome data for early intervention strategies. Additionally, exposome factors significant in identifying CVD risk were pinpointed, including daytime naps, completed full-time education, past tobacco smoking, frequency of tiredness/unenthusiasm, and current work status.

Indexed as

Artificial intelligenceCardiovascular diseaseClinical recordsExposomeMachine learning

Identifiers

PMID39834417
PMCPMC11742829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.